GSK Stock Recent News
GSK LATEST HEADLINES
GSK PLC (LSE:GSK, NYSE:GSK) cancer discovery Blenrep's blockbuster potential has been 'reawakened', according to Shore Capital. The broker was commenting after Thursday's phase III results, which showed the drug performed significantly better than the standard of care in patients with a hard-to-treat blood-borne cancer called multiple myeloma.
GSK said on Thursday a study showed its experimental drug Blenrep helped extend survival in patients with a type of blood cancer without symptoms worsening, marking a potential comeback for the drug after several setbacks.
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with GSK (GSK) and Vertex Pharmaceuticals (VRTX). But which of these two stocks presents investors with the better value opportunity right now?
The World Health Organization said on Tuesday that data shows resistance to the drug is growing in patients receiving GSK's HIV drug, dolutegravir.
GSK said on Monday a new formulation of its HIV prevention and treatment drug could potentially be administered at least every four months, an improvement from the previous requirement of dosing every two months.
Glaxo (GSK) reported earnings 30 days ago. What's next for the stock?
GSK PLC (LSE:GSK, NYSE:GSK) has confidentially settled a lawsuit in California that claimed its now-discontinued heartburn medication, Zantac, caused cancer. This agreement, ahead of a trial scheduled for April 2, is one of a series as the UK drugs giant attempts to head off expensive and time-consuming litigation.
GSK agreed to confidentially settle another lawsuit in California that had alleged its discontinued heartburn drug Zantac caused cancer, the latest in a series of settlements made by the British drugmaker to end costly litigation.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Glaxo (GSK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).